QUIDEL CORP Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows in 2012. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2012-12-07: Reporting owner TAMERIUS JOHN; Form 4; Security Incentive Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-12-06: Reporting owner POLAN MARY LAKE PH D; Form 4; Security Non-Qualified Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-12-06: Reporting owner POLAN MARY LAKE PH D; Form 4; Security Non-Qualified Stock Option; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2012-11-29: Reporting owner Brown Thomas D; Form 4; Security Non-Qualified Stock Option; Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2012-12-07 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Incentive Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,000 0 owned after | $3.19 exercise price | 2012-12-11 | |
| 2012-12-06 | POLAN MARY LAKE PH D Director | 4 | Non-Qualified Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,750 0 owned after | $5.44 exercise price | 2012-12-10 | |
| 2012-12-06 | POLAN MARY LAKE PH D Director | 4 | Non-Qualified Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,331 0 owned after | $9.93 exercise price | 2012-12-10 | |
| 2012-11-29 | Brown Thomas D Director | 4 | Non-Qualified Stock Option Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −5,331 0 owned after | $9.93 exercise price | 2012-11-29 | |
| 2012-11-27 | Brown Thomas D Director | 4 | Non-Qualified Stock Option Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −4,000 5,331 owned after | $9.93 exercise price | 2012-11-29 | |
| 2012-05-15 | SCHULER JACK W Director, 10% Owner | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,800 7,800 owned after | $15.73 exercise price | 2012-05-17 | |
| 2012-05-15 | PULIDO MARK Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,239 10,239 owned after | $15.73 exercise price | 2012-05-17 | |
| 2012-05-15 | POLAN MARY LAKE PH D Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,800 7,800 owned after | $15.73 exercise price | 2012-05-17 | |
| 2012-05-15 | Dammeyer Rodney F Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,800 7,800 owned after | $15.73 exercise price | 2012-05-17 | |
| 2012-05-15 | BUECHLER KENNETH F Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,800 7,800 owned after | $15.73 exercise price | 2012-05-17 | |
| 2012-05-15 | Brown Thomas D Director | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,800 7,800 owned after | $15.73 exercise price | 2012-05-17 | |
| 2012-03-02 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,031 35,031 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-03-02 | STEWARD RANDALL J Officer (Chief Financial Officer) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,125 31,125 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-03-02 | Stenzel Timothy Todd Officer (Chief Science Officer) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,038 42,038 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-03-02 | SMITS MARK W Officer (SVP-Commercial Operations) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,031 35,031 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-03-02 | McLeod Scot M Officer (SVP - Operations) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,125 31,125 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-03-02 | Bujarski Robert Joseph Officer (SVP, General Counsel & Secy) | 4 | Non-Qualified Stock Options Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,038 42,038 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-03-02 | BRYANT DOUGLAS C Director, Officer (President & CEO) | 4 | Non-Qualified Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +120,393 120,393 owned after | $15.19 exercise price | 2012-03-06 | |
| 2012-02-21 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Incentive Stock Options Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,625 0 owned after | $5.70 exercise price | 2012-03-06 | |
| 2012-02-21 | TAMERIUS JOHN Officer (SVP - Clinical/Reg Affairs) | 4 | Incentive Stock Options Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,625 0 owned after | $5.70 exercise price | 2012-03-06 |